Trabectedin (Yondelis (TM), formerly ET-743), a mass balance study in patients with advanced cancer

Research output: Contribution to journal › Article › Academic › peer-review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{156702362c44462c917694639d5d8e53,

title = "Trabectedin (Yondelis (TM), formerly ET-743), a mass balance study in patients with advanced cancer",

author = "J.H. Beumer and J.M. Rademaker-Lakhai and H. Rosing and L. Lopez-Lazaro and J.H. Beijnen and J.H.M. Schellens",

year = "2005",

language = "Undefined/Unknown",

volume = "23",

pages = "429--436",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Trabectedin (Yondelis (TM), formerly ET-743), a mass balance study in patients with advanced cancer

AU - Beumer, J.H.

AU - Rademaker-Lakhai, J.M.

AU - Rosing, H.

AU - Lopez-Lazaro, L.

AU - Beijnen, J.H.

AU - Schellens, J.H.M.

PY - 2005

Y1 - 2005

M3 - Article

SN - 0167-6997

VL - 23

SP - 429

EP - 436

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 5

ER -